Theratechnologies (THTX) Issues Update on Preclinical Oncology Research Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to Theratechnologies (THTX) Issues Update on Preclinical Oncology Research Program

Theratechnologies Announces Update on its Preclinical Oncology Research Program

March 22, 2024 9:36 AM EDT

Company continues to shift to commercial focus as it seeks partners to advance R&D

MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities. The Company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian... More